Article thumbnail

Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.

By Rory Leisegang, Susan Cleary, Michael Hislop, Alistair Davidse, Leon Regensberg, Francesca Little and Gary Maartens

Abstract

BACKGROUND: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care programme in Southern Africa. METHODS/FINDINGS: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell count criterion for starting ART was <350 cells/microl. We explored associations between variables and mean total costs over time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735 patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and viral load were 125 cells/microl and 5.16 log(10) copies/ml respectively. There was a peak in costs in the period around ART initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART; whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and starting ART at an older age. CONCLUSIONS: Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs. Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART. Please see later in the article for the Editors' Summary

Topics: Medicine, R
Publisher: Public Library of Science (PLoS)
Year: 2009
DOI identifier: 10.1371/journal.pmed.1000189
OAI identifier: oai:doaj.org/article:7ad6a739f5ab4460b3c3869a1674b38c
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1549-1676 (external link)
  • https://doaj.org/toc/1549-1277 (external link)
  • http://europepmc.org/articles/... (external link)
  • https://doaj.org/article/7ad6a... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles